A Post-Marketing Observational Surveillance Programme for Ambrisentan (VOLT)

Trial Profile

A Post-Marketing Observational Surveillance Programme for Ambrisentan (VOLT)

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Mar 2017

At a glance

  • Drugs Ambrisentan (Primary)
  • Indications Pulmonary hypertension
  • Focus Adverse reactions
  • Acronyms VOLT
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 16 Jun 2016 New trial record
    • 06 May 2016 Results published in the Journal of Heart and Lung Transplantation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top